Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?
Objective: Osteoarthritis (OA) is heterogeneous disease, for which drug development has proven to be challenging, both facilitated and hampered by changing guidelines. This is evident by the current lack of approved treatments, which improve joint function and delay joint failure. There is a need to...
| Glavni autori: | , , , , , , , |
|---|---|
| Format: | Članak |
| Jezik: | English |
| Izdano: |
Elsevier
2022-09-01
|
| Serija: | Osteoarthritis and Cartilage Open |
| Teme: | |
| Online pristup: | http://www.sciencedirect.com/science/article/pii/S2665913122000309 |